According to DelveInsight analysis, the Dystrophic Epidermolysis Bullosa market is expected to witness significant growth between 2024 and 2034 |Major players include Krystal Biotech, Chiesi, Phoenix Therapeutics, Aegle Therapeutics, Anterogen, and others.
Prominent Dystrophic Epidermolysis Bullosa market participants include Krystal Biotech, Chiesi, Phoenix Therapeutics, Aegle Therapeutics, Anterogen Co., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals, and others.
DelveInsight's comprehensive report, "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market...
0 Comments
0 Shares
French
Dutch